We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 61

Decoding patent-eligibility of diagnostic methods
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2016

Figuring out whether an invention is patent-worthy has become a bit easier, thanks to the Federal Circuit’s clarifications in Genetic Technologies


New infringement lawsuit filed to protect BRCA1 and BRCA2 patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 26 2014

Myriad Genetics has brought a new infringement lawsuit against a company offering a next-generation sequencing test that analyzes the BRCA1 and BRCA2


Australian court finds human gene mutation to be patentable
  • Shook Hardy & Bacon LLP
  • Australia, USA
  • September 11 2014

A full panel of the Federal Court of Australia has upheld its earlier ruling that an isolated but naturally occurring nucleic acid, BRCA1, can be


Federal Courts of Appeals conflict over validity of pay-for-delay deals
  • Shook Hardy & Bacon LLP
  • USA
  • August 2 2012

The Third Circuit Court of Appeals issued a ruling in mid-July that found “any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market must be treated by a factfinder as prima facie evidence of an unreasonable restraint of trade,” thus supporting the Federal Trade Commission’s (FTC’s) view that pay-for-delay deals that settle patent disputes between name-brand pharmaceutical companies and their generic drug competitors violate antitrust law


Myriad Genetics brings new BRCA1BRCA2 infringement suits
  • Shook Hardy & Bacon LLP
  • USA
  • December 12 2013

Myriad Genetics now reportedly has six pending infringement lawsuits involving its BRCA1 and BRCA2 patents, with Invitae Corp. and Laboratory Corp


Here, there, & everywhere: jurisdiction & venue in patent cases
  • Shook Hardy & Bacon LLP
  • USA
  • April 30 2016

Venue shopping can exert strong influence on patent suit success, causing litigants, courts, and legislatures to wrestle with boundaries. The Federal


U.S. Supreme Court to consider just one question in Myriad Genetics
  • Shook Hardy & Bacon LLP
  • USA
  • December 6 2012

The U.S. Supreme Court has agreed to review a Federal Circuit Court of Appeals ruling on the patentability of human genes and limited its grant of certiorari to the question “Are human genes patentable?”


Eleventh Circuit turns aside FTC challenge to pay-for-delay deal
  • Shook Hardy & Bacon LLP
  • USA
  • May 3 2012

The Eleventh Circuit Court of Appeals has dismissed an antitrust action filed by the Federal Trade Commission (FTC) against a name-brand prescription drug manufacturer (the patent holder) and generic drug companies that entered into pay-for-delay agreements to settle patent infringement claims filed against the generic drug companies


SCOTUS hears arguments on patentability of human genes
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

The U.S. Supreme Court (SCOTUS) heard arguments on Monday specifically addressing whether "human genes are patentable." Ass'n for Molecular Pathology


Second Circuit antitrust decision creates uncer tainty for non-practice of patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 11 2015

The U.S. Court of Appeals for the Second Circuit's recent decision in New York v. Actavis PLC appeared on its face to address a narrow issue of